Jasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024 - Jasper Therapeutics (NASDAQ:JSPR)

REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting

Related Keywords

Granada ,Andalucísp ,Spain ,Valencia ,Carabobo ,Venezuela ,United States ,Lauren Walker ,Alex Gray ,Joyce Allaire ,Edwin Tucker ,European Academy Of Allergy ,Jasper Therapeutics Inc ,Single Subcutaneous Sc Administration To Healthy ,European Academy ,Clinical Immunology ,Kit Mouse ,Wendy Pang ,Senior Vice President ,Translational Medicine ,Chief Medical Officer ,Dose Escalation Study ,Preliminary Clinical Activity ,Kit Mab Briquilimab ,Chronic Spontaneous Urticaria ,Oral Abstract ,Chronic Urticaria ,Mice Expressing Chimeric ,Flash Talks ,Allergic Response ,Single Subcutaneous ,Healthy Male ,Epithelial Cell ,Dose Escalation Trial ,Adult Patients ,Chronic Inducible Urticaria ,Who Remain Symptomatic Despite Treatment ,Mouse Model Expressing Chimeric ,Cutting Edge Mastocytosis ,Jasper Therapeutics ,Annual Report ,Quarterly Reports ,